Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Y-Mabs Therapeutics (YMAB)
NASDAQ:YMAB
Y-Mabs Therapeutics (YMAB) Stock Price & Analysis
201 Followers
YMAB Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.60 - $20.90
Previous Close$12.27
Volume355.13K
Average Volume (3M)373.33K
Market Cap
$538.44M
Enterprise Value$461.22M
Total Cash (Recent Filing)$78.64M
Total Debt (Recent Filing)$1.42M
Price to Earnings (P/E)―
Beta1.77
Next Earnings
Aug 08, 2024EPS Estimate
-$0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding43,882,638
10 Day Avg. Volume317,257
30 Day Avg. Volume373,334
Standard Deviation0.23
R-Squared0.03
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)5.42
Price to Sales (P/S)6.35
Price to Cash Flow (P/CF)-16.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.44
Enterprise Value/Gross Profit6.28
Enterprise Value/Ebitda-36.21
Forecast
1Y Price Target
$34.50Price Target Upside187.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Y-Mabs Therapeutics News
PremiumCompany Announcements
Y-mAbs Therapeutics Board Member Dr. Ber Announces Resignation
PremiumPress Releases
Y-mAbs to Present at 2024 ASCO Annual Meeting
PremiumCompany Announcements
Y-Mabs Therapeutics CFO Resigns, Ensures Smooth TransitionBulls Say, Bears Say
Bulls Say
Financial GuidanceY-mAbs provided 2024 financial guidance with expected DANYELZA revenues of $95-100M and projected annual cash burn of $15-20M, indicating a solid financial position.
Product PerformanceDANYELZA generated $23.4M in 4Q23, representing a 17.1% increase versus the previous quarter and has been shipped to more cancer centers.
Stock RatingAnalyst reiterates a Buy rating and raises the 12-month price target to $22, after updating the discounted cash flow (DCF)-based valuation.
Bears Say
EarningsY-mAbs recorded a net loss greater than the previously forecast.
International PerformanceInternational choppiness leads to Danyelza sales missing the consensus.
Sales PerformanceDANYELZA sales have decreased compared to the previous quarter.
---
Ownership Overview
29.86% Insiders
9.69% Mutual Funds
27.78% Other Institutional Investors
32.67% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
YMAB FAQ
What was Y-Mabs Therapeutics’s price range in the past 12 months?
Y-Mabs Therapeutics lowest stock price was $4.60 and its highest was $20.90 in the past 12 months.
What is Y-Mabs Therapeutics’s market cap?
Currently, no data Available
When is Y-Mabs Therapeutics’s upcoming earnings report date?
Y-Mabs Therapeutics’s upcoming earnings report date is Aug 08, 2024 which is in 69 days.
How were Y-Mabs Therapeutics’s earnings last quarter?
Y-Mabs Therapeutics released its earnings results on May 07, 2024. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.136 by -$0.014.
Is Y-Mabs Therapeutics overvalued?
According to Wall Street analysts Y-Mabs Therapeutics’s price is currently Undervalued.
Does Y-Mabs Therapeutics pay dividends?
Y-Mabs Therapeutics does not currently pay dividends.
What is Y-Mabs Therapeutics’s EPS estimate?
Y-Mabs Therapeutics’s EPS estimate is -$0.11.
How many shares outstanding does Y-Mabs Therapeutics have?
Y-Mabs Therapeutics has 43,882,637 shares outstanding.
What happened to Y-Mabs Therapeutics’s price movement after its last earnings report?
Y-Mabs Therapeutics reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.136. Following the earnings report the stock price went down -20.918%.
Which hedge fund is a major shareholder of Y-Mabs Therapeutics?
Among the largest hedge funds holding Y-Mabs Therapeutics’s share is Caxton Associates LP. It holds Y-Mabs Therapeutics’s shares valued at 306K.
---
Y-Mabs Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$34.50 (187.26% Upside)
$34.50 (187.26% Upside)
Blogger Sentiment
Neutral
YMAB Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 23.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $515.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 6.3%
Last 30 Days ▼ 6.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.03%
12-Months-Change
Fundamentals
Return on Equity
-20.93%
Trailing 12-Months
Asset Growth
-10.28%
Trailing 12-Months
Company Description
Y-Mabs Therapeutics
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company's services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
---
YMAB Earnings Call
Q1 2024
0:00 / 0:00
---
YMAB Stock 12 Month Forecast
Average Price Target
$34.50
▲(187.26% Upside)
Technical Analysis
Best Analysts Covering YMAB
1 Year
1 Year Success Rate
8/12 ratings generated profit
1 Year Average Return
+65.71%
reiterated a buy rating 24 days ago
Copying William Maughan's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +65.71% per trade.
---